{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:36:08Z","timestamp":1774917368154,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Welocalize Life Sciences"},{"name":"Vifor Pharma Espa\u00f1a"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective multicentre study, without any influence on the prescription decisions, that included 220 patients from 11 Spanish centres. Demographic, treatment, analytical and nutritional parameters and adherence, side effects and dropout rates were collected during 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SO was initiated due to inadequate control of serum phosphate (P) in 70% of participants and in 24.5% to reduce the number of tablets. Monotherapy with SO increased from 44% to 74.1%, with a reduction in the average daily number of sachets\/tablets from six to two. Serum P decreased by 20% (4.6\u2009\u00b1\u20091.2 versus 5.8\u2009\u00b1\u20091.3\u2009mg\/dL; P\u2009&amp;lt;\u20090.001), with a significant reduction in intact parathyroid hormone levels (P\u2009&amp;lt;\u20090.01). The percentage of patients with adequate serum P control at threshold levels of 5 and 4.5\u2009mg\/dL increased by 45.4% and 35.9%, respectively. Serum ferritin was not modified, while the transferrin saturation index increased significantly (P\u2009=\u20090.04). Serum albumin and normalized protein catabolic rate, when normalized by serum P, increased, averaging 37% and 39%, respectively (P\u2009&amp;lt;\u20090.001). Adherent patients increased from 28.2% to 52.7%. Adverse effects were reported by 14.1% of participants, with abandonment of treatment in 9.5%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of SO in real-life results in better control of serum P, a reduction in the number of tablets and an improvement in therapeutic adherence. In addition, it may be beneficial with regards to secondary hyperparathyroidism and nutritional status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaa226","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:22:50Z","timestamp":1603279370000},"page":"681-687","source":"Crossref","is-referenced-by-count":6,"title":["Real-world management of hyperphosphataemia with\u00a0sucroferric oxyhydroxide: the VELREAL multicentre study"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-7474","authenticated-orcid":false,"given":"Juan F","family":"Navarro-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Servicio de Nefrolog\u00eda y Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Santa Cruz de Tenerife, Spain"},{"name":"Instituto de Tecnolog\u00edas Biom\u00e9dicas, Universidad de La Laguna, Santa Cruz de Tenerife, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN \u2013 RD16\/0009), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"ERA-EDTA Working Group on CKD-MBD, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Arenas","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital del Mar, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Henr\u00edquez-Palop","sequence":"additional","affiliation":[{"name":"Centro de Di\u00e1lisis Avericum Norte, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-7062","authenticated-orcid":false,"given":"Mar\u00eda Jes\u00fas","family":"Lloret","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Fundaci\u00f3 Puigvert, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-6214","authenticated-orcid":false,"given":"Pablo","family":"Molina","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital Universitario Dr. Peset, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"R\u00edos Moreno","sequence":"additional","affiliation":[{"name":"Centro Di\u00e1lisis San Luciano, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Macia-Lagier","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital General de La Palma, Santa Cruz de La Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Espinel","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital Universitario de Getafe, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital Universitario de Cabue\u00f1es, Gij\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Lago","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Complejo Hospitalario Universitario Insular, Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crespo","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital Marina Baixa, Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n Renal (REDINREN \u2013 RD16\/0009), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Servicio de Nefrolog\u00eda, Fundaci\u00f3 Puigvert, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"2021021623485890300_sfaa226-B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000443848","article-title":"Association between hemodialysis patient outcomes and compliance with KDOQI and KDIGO targets for mineral and bone metabolism","volume":"132","author":"Djukanovi\u0107","year":"2016","journal-title":"Nephron"},{"key":"2021021623485890300_sfaa226-B2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.jrn.2013.01.018","article-title":"Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients","volume":"23","author":"Lertdumrongluk","year":"2013","journal-title":"J Ren Nutr"},{"key":"2021021623485890300_sfaa226-B3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"2021021623485890300_sfaa226-B4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14656566.2018.1491548","article-title":"Sucroferric oxyhydroxide for the treatment of hyperphosphatemia","volume":"19","author":"Sprague","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2021021623485890300_sfaa226-B5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"2021021623485890300_sfaa226-B6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of\u00a0the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021021623485890300_sfaa226-B7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology (Carlton"},{"key":"2021021623485890300_sfaa226-B8","first-page":"884","article-title":"KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update","volume":"66","year":"2015"},{"key":"2021021623485890300_sfaa226-B9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487856","article-title":"Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide","volume":"47","author":"Kalantar-Zadeh","year":"2018","journal-title":"Am J Nephrol"},{"key":"2021021623485890300_sfaa226-B10","first-page":"428","article-title":"One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis","volume":"29","author":"Kendrick","year":"2019","journal-title":"J\u00a0Ren Nutr"},{"key":"2021021623485890300_sfaa226-B11","first-page":"525","article-title":"Challenge of phosphorus control in hemodialysis patients: a problem of adherence?","volume":"23","author":"Arenas","year":"2010","journal-title":"J\u00a0Nephrol"},{"key":"2021021623485890300_sfaa226-B12","first-page":"196","article-title":"Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study","volume":"33","author":"Dolores Arenas","year":"2013","journal-title":"Nefrologia"},{"key":"2021021623485890300_sfaa226-B13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CN109021","article-title":"Real-world effectiveness of sucroferric oxyhydroxyde in patients on chronic hemodialysis: a restrospective analysis of pharmacy data","volume":"88","author":"Coyne","year":"2017","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"2021021623485890300_sfaa226-B14","first-page":"3","article-title":"Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrolog\u00eda"},{"key":"2021021623485890300_sfaa226-B15","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.05560809","article-title":"Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis","volume":"4","author":"Vilar","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021021623485890300_sfaa226-B16","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ndt\/gfy035","article-title":"Haemodialysis or\u00a0haemodiafiltration: that is the question","volume":"33","author":"Locatelli","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2021021623485890300_sfaa226-B17","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2021021623485890300_sfaa226-B18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2021021623485890300_sfaa226-B19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyprphosphatemia in chronic kidney disease","volume":"74","author":"Geisser","year":"2010","journal-title":"Clin Nephrol"},{"key":"2021021623485890300_sfaa226-B20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"2021021623485890300_sfaa226-B21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1389200216666150206124424","article-title":"Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide","volume":"15","author":"Cozzolino","year":"2015","journal-title":"Curr Drug Metab"},{"key":"2021021623485890300_sfaa226-B22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/2175-8239-jbn-2018-0142","article-title":"Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: a retrospective study","volume":"41","author":"Ferreira","year":"2019","journal-title":"J Bras Nefrol"},{"key":"2021021623485890300_sfaa226-B23","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021021623485890300_sfaa226-B24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gft269","article-title":"Iron toxicity: relevance for dialysis patients","volume":"29","author":"Fishbane","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2021021623485890300_sfaa226-B25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2021021623485890300_sfaa226-B26","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2021021623485890300_sfaa226-B27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2215\/CJN.04620510","article-title":"Prescribed dietary phosphate restriction and survival among hemodialysis patients","volume":"6","author":"Lynch","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021021623485890300_sfaa226-B28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2215\/CJN.13141216","article-title":"Longitudinal associations among renal urea clearance-corrected normalized protein catabolic rate, serum albumin, and mortality in patients on hemodialysis","volume":"12","author":"Eriguchi","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021021623485890300_sfaa226-B29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12882-019-1582-9","article-title":"Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study","volume":"20","author":"Kalantar-Zadeh","year":"2019","journal-title":"BMC Nephrol"},{"key":"2021021623485890300_sfaa226-B30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021021623485890300_sfaa226-B31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1744-9987.2012.01098.x","article-title":"Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis","volume":"17","author":"Hung","year":"2013","journal-title":"Ther Apher Dial"},{"key":"2021021623485890300_sfaa226-B32","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"Wang","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/2\/681\/36283993\/sfaa226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/2\/681\/36283993\/sfaa226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:52:12Z","timestamp":1613742732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/2\/681\/6125308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa226","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2021,2,1]]}}}